Abstract
Fluoroquinolones are variably active against methicillin-resistantStaphylococcus aureus (MRSA) and methicillin-resistantStaphylococcus epidermidis (MRSE). The purpose of this study was to test the in vitro susceptibility of 50 isolates each of MRSA and MRSE to four of the new fluoroquinolones — sparfloxacin, ciprofloxacin, ofloxacin and norfloxacin — and to see if resistance could be induced in five susceptible strains of each species by serial passage with increasing concentrations of drug. A standard microdilution technique was used to determine minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of each drug for each isolate. Agar dilution plates were also prepared containing concentrations of drug varying from one-half of the reported MIC to 128 times the reported MIC, and microorganisms persisting were serially passaged. Initially, 98 % of the strains of MRSA were susceptible to the fluoroquinolones. MBCs were essentially identical to MICs. Similarly, 96 % of the strains of MRSE were susceptible. Following exposure to increasing concentrations of each fluoroquinolone, resistance appeared to emerge less rapidly to sparfloxacin and ofloxacin than to norfloxacin and ciprofloxacin.
Similar content being viewed by others
References
Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cortes H, Merlo A Ciprofloxacin-resistant methicillin-resistantStaphylococcus aureus in an acute-care hospital. Antimicrobial Agents and Chemotherapy 1990, 34: 2050–2054.
Daum TE, Schaberg DR, Terpenning MS, Sottile WS, Kauffman CA Increasing resistance ofStaphylococcus aureus to ciprofloxacin. Antimicrobial Agents and Chemotherapy 1990, 34: 1862–1863.
Chaudhry AZ, Knapp CC, Sierra-Madero J, Washington JA Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 1990, 34: 1843–1845.
Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y, Kashimoto S, Yoshida H, Kojima T, Ohue T, Fujimoto K, Nakamura M, Hashimoto M, Shimizu M In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 1989, 33: 1167–1173.
Kojima T, Inoue M, Mitsuhashi S In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 1989, 33: 1980–1988.
National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A4. NCCLS, Villanova, PA, 1990.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1990.
Pearson RD, Steigbigel RT, Davis HT, Chapman SW Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrobial Agents and Chemotherapy 1980, 18: 699–708.
Simor AE, Fuller SA, Low DE Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 1990, 34: 2283–2286.
Rolston KVI, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrobial Agents and Chemotherapy 1990, 34: 2263–2266.
Forstall GJ, Knapp CC, Washington JA Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrobial Agents and Chemotherapy 1991, 35: 1679–1681.
Chin NX, Gu JW, Yu KW, Zhang YX, Neu HC In vitro activity of sparfloxacin. Antimicrobial Agents and Chemotherapy 1991, 35: 567–571.
Barry AL, Fuchs PC In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrobial Agents and Chemotherapy 1991, 35: 955–960.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, K.R., Cobbs, C.G. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistantStaphylococcus aureus andStaphylococcus epidermidis . Eur. J. Clin. Microbiol. Infect. Dis. 11, 55–58 (1992). https://doi.org/10.1007/BF01971273
Issue Date:
DOI: https://doi.org/10.1007/BF01971273